Trial Profile
Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Combretastatin A1 phosphate (Primary) ; Cytarabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mateon Therapeutics
- 27 Dec 2019 Results published in the Media Release
- 27 Dec 2019 Status changed from recruiting to completed in August 2019 , according to a Mateon Therapeutics media release.
- 27 Dec 2019 According to a Mateon Therapeutics media release, data were published in the prestigious oncology journal Cancers (Basel), co-authored by Fatih Uckun MD. PhD, the Chief Medical Officer for Mateon, Vuong Trieu, PhD, the Chief Executive Officer and President for Mateon and four hematology/oncology professors from academic US institutions.